Skip to main content
Erschienen in: Journal of Neurology 9/2016

10.06.2016 | Original Communication

Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases

verfasst von: Hisanori Kinoshita, Hodaka Yamakado, Toshiyuki Kitano, Akihiro Kitamura, Hirofumi Yamashita, Masakazu Miyamoto, Takefumi Hitomi, Tomohisa Okada, Yuji Nakamoto, Nobukatsu Sawamoto, Akifumi Takaori-Kondo, Ryosuke Takahashi

Erschienen in: Journal of Neurology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Neurolymphomatosis (NL) is a rare condition involving the infiltration of lymphoma cells into the peripheral nervous system. NL can be primary or secondary in the setting of an unknown or known hematologic malignancy, respectively. Here, we report five cases in which F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (F-18 FDG-PET/CT) had great value for diagnosing NL. Two cases were rare primary NL, and the other three were secondary NL. Clinical presentations were asymmetric sensorimotor disturbances in the extremities with or without involvement of cranial nerves. Furthermore, all patients experienced spontaneous pain in the face or affected extremities. Cerebrospinal fluid analysis was cytologically negative in two of five cases. Gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) detected abnormalities in the cranial nerves, nerve roots, and cauda equina in all cases except case 1 and the recurrent stage of case 2. F-18 FDG-PET/CT showed clear visualization of almost all the lymphomatous involvement of peripheral nerves and other tissues in all patients. Furthermore, F-18 FDG-PET/CT detected abnormalities including asymptomatic lesions that were not detected with MRI, and also identified the appropriate lesion for diagnostic biopsy. However, as in case 3, the lesions in the left oculomotor nerve and the cauda equina were detected only with Gd-enhanced MRI, which has superior spatial resolution. In conclusion, F-18 FDG-PET/CT is a sensitive modality that can suggest the presence of malignancy and identify appropriate places for diagnostic biopsies. It is especially useful when combined with Gd-enhanced MRI, even in patients with primary NL that is usually difficult to diagnose.
Literatur
1.
Zurück zum Zitat Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T, International Primary CNS Lymphoma Collaborative Group (2010) Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood 115:5005–5011CrossRefPubMedPubMedCentral Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T, International Primary CNS Lymphoma Collaborative Group (2010) Neurolymphomatosis: an international primary CNS lymphoma collaborative group report. Blood 115:5005–5011CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat van den Bent MJ, de Bruin HG, Bos GM, Brutel de la Rivière G, Sillevis Smitt PA (1999) Negative sural nerve biopsy in neurolymphomatosis. J Neurol 246:1159–1163CrossRefPubMed van den Bent MJ, de Bruin HG, Bos GM, Brutel de la Rivière G, Sillevis Smitt PA (1999) Negative sural nerve biopsy in neurolymphomatosis. J Neurol 246:1159–1163CrossRefPubMed
4.
Zurück zum Zitat Tomita M, Koike H, Kawagashira Y, Iijima M, Adachi H, Taguchi J, Abe T, Sako K, Tsuji Y, Nakagawa M, Kanda F, Takeda F, Sugawara M, Toyoshima I, Asano N, Sobue G (2013) Clinicopathological features of neuropathy associated with lymphoma. Brain 136:2563–2578CrossRefPubMed Tomita M, Koike H, Kawagashira Y, Iijima M, Adachi H, Taguchi J, Abe T, Sako K, Tsuji Y, Nakagawa M, Kanda F, Takeda F, Sugawara M, Toyoshima I, Asano N, Sobue G (2013) Clinicopathological features of neuropathy associated with lymphoma. Brain 136:2563–2578CrossRefPubMed
5.
Zurück zum Zitat Nakajima S, Okada T, Yamamoto A, Kanagaki M, Fushimi Y, Okada T, Arakawa Y, Takagi Y, Miyamoto S, Togashi K (2015) Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography. Clin Imaging 39:390–395CrossRefPubMed Nakajima S, Okada T, Yamamoto A, Kanagaki M, Fushimi Y, Okada T, Arakawa Y, Takagi Y, Miyamoto S, Togashi K (2015) Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and (18)F-fluorodeoxyglucose positron emission tomography. Clin Imaging 39:390–395CrossRefPubMed
6.
Zurück zum Zitat Salm LP, Van der Hiel B, Stokkel MP (2012) Increasing importance of 18F-FDG PET in the diagnosis of neurolymphomatosis. Nucl Med Commun 33:907–916CrossRefPubMed Salm LP, Van der Hiel B, Stokkel MP (2012) Increasing importance of 18F-FDG PET in the diagnosis of neurolymphomatosis. Nucl Med Commun 33:907–916CrossRefPubMed
7.
Zurück zum Zitat Hong RS, Woodson EA, Hansen MR (2009) Neurolymphomatosis mimicking chemotherapy-induced ototoxicity. Otol Neurotol 30:566–569CrossRefPubMed Hong RS, Woodson EA, Hansen MR (2009) Neurolymphomatosis mimicking chemotherapy-induced ototoxicity. Otol Neurotol 30:566–569CrossRefPubMed
9.
Zurück zum Zitat Shaikh F, Chan AC, Awan O, Jerath N, Reddy C, Khan SA, Graham MM (2015) Diagnostic yield of FDG-PET/CT, MRI, and CSF cytology in non-biopsiable neurolymphomatosis as a heralding sign of recurrent non-Hodgkin’s lymphoma. Cureus 7:e319PubMedPubMedCentral Shaikh F, Chan AC, Awan O, Jerath N, Reddy C, Khan SA, Graham MM (2015) Diagnostic yield of FDG-PET/CT, MRI, and CSF cytology in non-biopsiable neurolymphomatosis as a heralding sign of recurrent non-Hodgkin’s lymphoma. Cureus 7:e319PubMedPubMedCentral
10.
Zurück zum Zitat Lahoria R, Dyck PJ, Macon WR, Crum BA, Spinner RJ, Amrami KK, Zeldenrust SR, Tracy JA (2015) Neurolymphomatosis: a report of 2 cases representing opposite ends of the clinical spectrum. Muscle Nerve 52:449–454CrossRefPubMed Lahoria R, Dyck PJ, Macon WR, Crum BA, Spinner RJ, Amrami KK, Zeldenrust SR, Tracy JA (2015) Neurolymphomatosis: a report of 2 cases representing opposite ends of the clinical spectrum. Muscle Nerve 52:449–454CrossRefPubMed
11.
Zurück zum Zitat Ropper AH, Samuels MA (2009) Diseases of the peripheral nerves. In: Ropper AH, Samuels MA (eds) Adams and Victor’s principles of neurology, 9th edn. McGraw-Hill Companies, New York, pp 1280–1287 Ropper AH, Samuels MA (2009) Diseases of the peripheral nerves. In: Ropper AH, Samuels MA (eds) Adams and Victor’s principles of neurology, 9th edn. McGraw-Hill Companies, New York, pp 1280–1287
12.
Zurück zum Zitat Saperstein DS, Amato AA, Wolfe GI, Katz JS, Nations SP, Jackson CE, Bryan WW, Burns DK, Barohn RJ (1999) Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 22:560–566CrossRefPubMed Saperstein DS, Amato AA, Wolfe GI, Katz JS, Nations SP, Jackson CE, Bryan WW, Burns DK, Barohn RJ (1999) Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 22:560–566CrossRefPubMed
13.
Zurück zum Zitat Bartels S, Kyavar L, Blumstein N, Görg T, Glöckner SC, Zimmermann R, Heckmann JG (2013) FDG PET findings leading to diagnosis of neurosarcoidosis. Clin Neurol Neurosurg 115:85–88CrossRefPubMed Bartels S, Kyavar L, Blumstein N, Görg T, Glöckner SC, Zimmermann R, Heckmann JG (2013) FDG PET findings leading to diagnosis of neurosarcoidosis. Clin Neurol Neurosurg 115:85–88CrossRefPubMed
14.
Zurück zum Zitat Glaudemans AW, Slart RH, Noordzij W, Dierckx RA, Hazenberg BP (2013) Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis. Eur J Nucl Med Mol Imaging 40:1095–1101CrossRefPubMed Glaudemans AW, Slart RH, Noordzij W, Dierckx RA, Hazenberg BP (2013) Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis. Eur J Nucl Med Mol Imaging 40:1095–1101CrossRefPubMed
15.
Zurück zum Zitat Broski SM, Spinner RJ, Howe BM, Dispenzieri A, Johnson GB (2016) 18F-florbetapir and 18F-FDG PET/CT in systemic immunoglobulin light chain amyloidosis involving the peripheral nerves. Clin Nucl Med 41:e115–e117CrossRefPubMed Broski SM, Spinner RJ, Howe BM, Dispenzieri A, Johnson GB (2016) 18F-florbetapir and 18F-FDG PET/CT in systemic immunoglobulin light chain amyloidosis involving the peripheral nerves. Clin Nucl Med 41:e115–e117CrossRefPubMed
16.
Zurück zum Zitat Cheson BD (2011) Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844–1854CrossRefPubMed Cheson BD (2011) Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844–1854CrossRefPubMed
Metadaten
Titel
Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases
verfasst von
Hisanori Kinoshita
Hodaka Yamakado
Toshiyuki Kitano
Akihiro Kitamura
Hirofumi Yamashita
Masakazu Miyamoto
Takefumi Hitomi
Tomohisa Okada
Yuji Nakamoto
Nobukatsu Sawamoto
Akifumi Takaori-Kondo
Ryosuke Takahashi
Publikationsdatum
10.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 9/2016
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-016-8190-4

Weitere Artikel der Ausgabe 9/2016

Journal of Neurology 9/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.